The stock of Eleven Biotherapeutics Inc (NASDAQ:EBIO) is a huge mover today! About 2.39M shares traded hands or 43.98% up from the average. Eleven Biotherapeutics Inc (NASDAQ:EBIO) has risen 771.64% since April 13, 2016 and is uptrending. It has outperformed by 767.71% the S&P500.
The move comes after 8 months negative chart setup for the $57.32M company. It was reported on Nov, 15 by Barchart.com. We have $2.22 PT which if reached, will make NASDAQ:EBIO worth $7.45M less.
Eleven Biotherapeutics Inc (NASDAQ:EBIO) Ratings Coverage
Out of 2 analysts covering Eleven Biotherapeutics (NASDAQ:EBIO), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Eleven Biotherapeutics has been the topic of 4 analyst reports since August 15, 2015 according to StockzIntelligence Inc. Leerink Swann maintained the stock with “Outperform” rating in Saturday, August 15 report. The firm has “Market Perform” rating given on Tuesday, January 19 by Leerink Swann. The firm has “Neutral” rating given on Tuesday, January 19 by Citigroup. Citigroup maintained the shares of EBIO in a report on Wednesday, March 16 with “Neutral” rating.
According to Zacks Investment Research, “Eleven Biotherapeutics, Inc. is engaged in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its principal preclinical product candidate consist of EBI-005, a novel IL-1 receptor antagonist for the topical treatment of dry eye disease and allergic conjunctivitis, EBI-029, a novel inhibitor of the cytokine IL-6 for the treatment of certain retinal diseases, such as DME and EBI-028, a novel inhibitor of the cytokine IL-17 for the treatment of uveitis. Eleven Biotherapeutics, Inc. is based in Cambridge, United States.”
Insitutional Activity: The institutional sentiment increased to 1 in 2016 Q2. Its up 0.62, from 0.38 in 2016Q1. The ratio is positive, as 5 funds sold all Eleven Biotherapeutics Inc shares owned while 4 reduced positions. 5 funds bought stakes while 4 increased positions. They now own 2.51 million shares or 36.45% more from 1.84 million shares in 2016Q1.
The New Jersey-based Kcg has invested 0% in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Goldman Sachs Grp Inc has 0% invested in the company for 13,343 shares. Blackrock Institutional Na owns 149,618 shares or 0% of their US portfolio. Financial Bank Of America Corporation De holds 0% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO) for 35 shares. Fiduciary Tru last reported 0% of its portfolio in the stock. Two Sigma Securities Ltd Liability Corp has invested 0.02% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Citigroup holds 0% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO) for 600 shares. Geode Capital Mngmt accumulated 46,637 shares or 0% of the stock. Morgan Stanley reported 1,503 shares or 0% of all its holdings. Renaissance Tech Lc reported 118,500 shares or 0% of all its holdings. Susquehanna Interest Group Inc Limited Liability Partnership holds 0% or 26,654 shares in its portfolio. Reilly Financial Ltd Com last reported 100 shares in the company. Royal Commercial Bank Of Canada reported 500 shares or 0% of all its holdings. Vanguard Inc holds 0% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO) for 77,656 shares. Flagship Ventures 2007 General Partner Lc holds 2.98% or 1.91M shares in its portfolio.
EBIO Company Profile
Eleven Biotherapeutics, Inc., incorporated on February 25, 2008, is a preclinical-stage biopharmaceutical company. The Firm applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.